TScan Therapeutics（NASDAQ:TCRX）报告第四季度每股亏损$(0.30)，未达到分析师一致预期的$(0.27)，差异为11.11%。与去年同期每股亏损$(0.21)相比，这是一个42.86%的下降。公司报告季度销售额为66.5万美元，未达到分析师一致预期的135万美元，差异为50.74%。与去年同期的721万美元销售额相比，这是一个90.78%的下降。
以上内容来自Benzinga Earnings专栏，原文如下：
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 42.86 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.35 million by 50.74 percent. This is a 90.78 percent decrease over sales of $7.21 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.